Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H46O4 |
Molecular Weight | 470.6838 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]3(C)C2=CC(=O)[C@]4([H])[C@@]5(C)CC[C@H](O)C(C)(C)[C@]5([H])CC[C@@]34C)C(O)=O
InChI
InChIKey=MPDGHEJMBKOTSU-YKLVYJNSSA-N
InChI=1S/C30H46O4/c1-25(2)21-8-11-30(7)23(28(21,5)10-9-22(25)32)20(31)16-18-19-17-27(4,24(33)34)13-12-26(19,3)14-15-29(18,30)6/h16,19,21-23,32H,8-15,17H2,1-7H3,(H,33,34)/t19-,21-,22-,23+,26+,27-,28-,29+,30+/m0/s1
Molecular Formula | C30H46O4 |
Molecular Weight | 470.6838 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 9 / 9 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/9570253 | https://www.ncbi.nlm.nih.gov/pubmed/8783808https://www.ncbi.nlm.nih.gov/pubmed/24493924 | https://www.ncbi.nlm.nih.gov/pubmed/19144869 | https://www.ncbi.nlm.nih.gov/pubmed/17613133 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=184.1408http://www.etatpur.co.uk/index.php/enoxolone-sheethttps://www.ncbi.nlm.nih.gov/pubmed/27376261https://www.ncbi.nlm.nih.gov/pubmed/17613133https://www.ncbi.nlm.nih.gov/pubmed/17613133 | http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2015.3971/pdf | http://www.cosmeticsinfo.org/ingredient/disodium-glycyrrhizate | http://www.google.com.pg/patents/WO2009115455A1https://www.ncbi.nlm.nih.gov/pubmed/17613133 | http://www.cosmeticsinfo.org/ingredient/potassium-glycyrrhetinateCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19429429 | https://www.ncbi.nlm.nih.gov/pubmed/27520483
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9570253 | https://www.ncbi.nlm.nih.gov/pubmed/8783808https://www.ncbi.nlm.nih.gov/pubmed/24493924 | https://www.ncbi.nlm.nih.gov/pubmed/19144869 | https://www.ncbi.nlm.nih.gov/pubmed/17613133 | https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=184.1408http://www.etatpur.co.uk/index.php/enoxolone-sheethttps://www.ncbi.nlm.nih.gov/pubmed/27376261https://www.ncbi.nlm.nih.gov/pubmed/17613133https://www.ncbi.nlm.nih.gov/pubmed/17613133 | http://onlinelibrary.wiley.com/doi/10.2903/j.efsa.2015.3971/pdf | http://www.cosmeticsinfo.org/ingredient/disodium-glycyrrhizate | http://www.google.com.pg/patents/WO2009115455A1https://www.ncbi.nlm.nih.gov/pubmed/17613133 | http://www.cosmeticsinfo.org/ingredient/potassium-glycyrrhetinate
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/19429429 | https://www.ncbi.nlm.nih.gov/pubmed/27520483
Potassium Glycyrrhetinate (CAS no. 85985-61-1) is the
potassium salt of Glycyrrhetinic Acid. Potassium Glycyrrhetinate
is also known as Olean-12-En-29-Oic Acid, 3-Hydroxy-1,
1-Oxo-, Monopotassium Salt. Potassium Glycyrrhetinate functions as a flavoring agent and skin-conditioning agent—miscellaneous in cosmetic products.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0072593 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19144869 |
|||
Target ID: Q9UBK2|||Q3LIG1 Gene ID: 10891.0 Gene Symbol: PPARGC1A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24675225 |
|||
Target ID: P24298 Gene ID: 2875.0 Gene Symbol: GPT Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/10574137 |
|||
Target ID: CHEMBL2391 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19429429 |
779.0 nM [IC50] | ||
Target ID: CHEMBL2908 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19429429 |
257.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Stronger Neo-Minophagen C Approved UseChronic Hepatitis C Launch Date1948 |
|||
Preventing | MASO65D (Xclair®) Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
|||
Palliative | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
103.89 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18452416 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENOXOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1396.97 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18452416 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENOXOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
9.46 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/18452416 |
150 mg single, oral dose: 150 mg route of administration: Oral experiment type: SINGLE co-administered: |
ENOXOLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
likely | ||||
yes [IC50 6.12 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://pubmed.ncbi.nlm.nih.gov/18204840/ Page: 6.0 |
likely | |||
Page: 1.0 |
major | |||
Page: 1.0 |
major | |||
Page: 1.0 |
minor | |||
Page: 1.0 |
minor | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Sources: https://pubmed.ncbi.nlm.nih.gov/18204840/ Page: 6.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
no | |||
Page: 1.0 |
yes | |||
Page: 1.0 |
yes | |||
Page: 1.0 |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
Therapeutic basis of glycyrrhizin on chronic hepatitis B. | 1996 May |
|
Regulation of the action of hydrocortisone in airway epithelial cells by 11beta-hydroxysteroid dehydrogenase. | 1999 Sep |
|
Endothelium-dependent vasorelaxation independent of nitric oxide and K(+) release in isolated renal arteries of rats. | 2001 Apr |
|
Liquorice-induced rise in blood pressure: a linear dose-response relationship. | 2001 Aug |
|
In vivo 11beta-HSD-2 activity: variability, salt-sensitivity, and effect of licorice. | 2001 Dec 1 |
|
Enzyme-linked immunosorbent assay for glycyrrhizin using anti-glycyrrhizin monoclonal antibody and an eastern blotting technique for glucuronides of glycyrrhetic acid. | 2001 Dec 15 |
|
Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5. | 2001 Jan 22 |
|
Persistence of gap junction communication during myocardial ischemia. | 2001 Jun |
|
Allergic contact dermatitis from enoxolone. | 2001 Mar |
|
Characterization of bovine angiogenin-1 and lactogenin-like protein as glycyrrhizin-binding proteins and their in vitro phosphorylation by C-kinase. | 2001 May |
|
Potentiation of L-type calcium channels reveals nonsynaptic mechanisms that correlate spontaneous activity in the developing mammalian retina. | 2001 Nov 1 |
|
[Prevention of development of hepatocellular carcinoma from HCV-associated liver cirrhosis by multi-agents therapy including stronger-neo-minophagen C]. | 2001 Oct |
|
An endothelium-derived hyperpolarizing factor-like factor moderates myogenic constriction of mesenteric resistance arteries in the absence of endothelial nitric oxide synthase-derived nitric oxide. | 2001 Oct |
|
LAF1, a MYB transcription activator for phytochrome A signaling. | 2001 Oct 1 |
|
Modulation of 11 beta-hydroxysteroid dehydrogenase type 2 activity in Ishikawa cells is associated with changes in cellular proliferation. | 2001 Oct 25 |
|
An unexpected case of primary pulmonary hypertension of the neonate (PPHN). Potential role of topical administration of enoxolone. | 2002 |
|
UDP-glucuronic acid:soyasapogenol glucuronosyltransferase involved in saponin biosynthesis in germinating soybean seeds. | 2002 Aug |
|
Cell coupling and Cx43 expression in embryonic mouse neural progenitor cells. | 2002 Aug 15 |
|
Short-term cortisol infusion in the brachial artery, with and without inhibiting 11 beta-hydroxysteroid dehydrogenase, does not alter forearm vascular resistance in normotensive and hypertensive subjects. | 2002 Dec |
|
[Effects of glycyrrhetinic acid and IFN-alpha on HSCs collagen metabolism in rat fibrotic liver of varying stages]. | 2002 Feb |
|
Critical role of gap junctions in endothelium-dependent hyperpolarization in rat mesenteric arteries. | 2002 Jul |
|
[Licorice--not just candy]. | 2002 Mar 20 |
|
Foetal lung maturation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice. | 2002 Oct |
|
Solubilization and stabilization of macular carotenoids by water soluble oligosaccharides and polysaccharides. | 2015 Apr 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21681505
Curator's Comment: Disodium Glycyrrhizate was not carcinogenic in mice in a drinking water study at exposure levels up to 12.2 mg/kg day(-1) for 96 weeks.
100 ml/day of intravenous glycyrrhizin
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7721345
Curator's Comment: The suppressor cell activity of T6S cells was clearly counteracted by glycyrrhizin mononuclear cells (GR-MNC) in vitro in a mixed lymphocyte-tumor cell reaction. The type of cells responsible for anti-suppressor cells in GR-MNC was shown to be a CD4+ CD28+ TCR alpha/beta + Vicia villosa lectin-adherent T cell. These results suggest that GR may reverse the increased susceptibility of thermally injured mice to herpes simplex virus type 1 (HSV) infection through the induction of CD4+ contrasuppressor T cells.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:18:46 GMT 2023
by
admin
on
Fri Dec 15 15:18:46 GMT 2023
|
Record UNII |
P540XA09DR
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C54678
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
||
|
DSLD |
3013 (Number of products:1)
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
||
|
WHO-VATC |
QD03AX10
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
||
|
WHO-ATC |
D03AX10
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P540XA09DR
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
30853
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
D006034
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
35347
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
m4914
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | Merck Index | ||
|
1794
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
P540XA09DR
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
10114
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
DB13089
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
100000080236
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
3178
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
471-53-4
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
207-444-6
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
GLYCYRRHETINIC ACID
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
DTXSID9020669
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
SUB06543MIG
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
C526
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL230006
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | |||
|
1311506
Created by
admin on Fri Dec 15 15:18:47 GMT 2023 , Edited by admin on Fri Dec 15 15:18:47 GMT 2023
|
PRIMARY | RxNorm |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |